Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win in lung cancer, this time as part of a chemotherapy combination.

Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

After enacting a “poison pill” defense to protect itself from unwanted potential buyers, Bausch Health has spotted a major ...

Two years ago, the Pharmaceutical Research and Manufacturers of America (PhRMA) trade group faced a mini-exodus as several ...

With the threat of pharmaceutical tariffs hanging over the biopharmaceutical industry, Roche is the latest addition to a ...

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

More than 90% of dermatology clinicians surveyed by Leo Pharma say their patients with moderate to severe chronic hand eczema ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...